文献速递甲状腺与颈部外科围术期管理与 ERAS

甲状腺及甲状旁腺手术加速康复外科路径的早期观察:目标前移

Early observations with an ERAS pathway for thyroid and parathyroid surgery: Moving the goalposts forward.
PubMed 文献 · Surgery · 2023-11-15

本研究比较了本机构内分泌外科医生实施的甲状腺/甲状旁腺手术在加速康复外科(ERAS)多干预路径实施前1年(n=479)与实施后1年(n=166)的围术期结局及非预期入院情况,并比较了不同ERAS依从性患者组间的结局。结果显示ERAS与总住院时间显著缩短(9.2 vs 7.5小时,P<.0001)相关,ERAS组患者主动入院减少,术后吗啡毫克当量均值、日平均吗啡毫克当量及日平均疼痛评分均显著降低(尤其随ERAS依从性提高),术后止吐药需求及麻醉后监护室停留时间无显著差异。

要点

  • ERAS路径与甲状腺/甲状旁腺术后总住院时间显著缩短相关(9.2 vs 7.5小时,P<.0001)。
  • ERAS组术后吗啡毫克当量均值、日平均吗啡毫克当量及日平均疼痛评分显著降低,且随ERAS依从性提高更明显。
  • 术后止吐药需求及麻醉后监护室停留时间无显著差异。

核心结论

  • 本研究显示,即使基于初始数据和交错推出计划,ERAS路径对甲状腺切除术和甲状旁腺切除术仍具有显著获益。
  • 未来方向包括在机构对ERAS路径所有组成部分达到更高依从性后开展随访研究,以及开展前瞻性试验以明确ERAS路径不同组成部分(特别是颈浅丛阻滞)的相对重要性。

研究设计与样本

  • 本研究为本机构内分泌外科医生实施的所有甲状腺/甲状旁腺手术的干预前后比较,比较了多干预ERAS路径实施前1年(n=479)与实施后1年(n=166)的相关结局。
  • 研究还比较了ERAS依从性水平不同的ERAS患者组间的结局。

主要发现

  • ERAS与总住院时间显著缩短相关(9.2 vs 7.5小时,P<.0001)。
  • 全因非预期术后入院无显著减少,但ERAS组患者主动入院减少。
  • ERAS组(尤其随ERAS依从性提高)术后吗啡毫克当量均值显著降低(14.4 vs 16.2 vs 24.8,P=.0015)。
  • ERAS组(尤其随ERAS依从性提高)日平均吗啡毫克当量显著降低(25.6 vs 45.6 vs 53,P<.0001)。
  • ERAS组(尤其随ERAS依从性提高)日平均疼痛评分显著降低(1.89 vs 2.38 vs 2.74,P=.0045)。

局限性

  • 本研究基于初始数据,采用交错推出计划。
  • 需在机构对ERAS路径所有组成部分达到更高依从性后开展随访研究,并需前瞻性试验明确ERAS路径不同组成部分的相对重要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhanced recovery after surgery pathways have become the standard of care in various surgical specialties. In this study, we discuss our initial experience with a staged enhanced recovery after surgery pathway in endocrine surgery and assess the impact of this pathway on select perioperative outcomes and unanticipated admissions. METHODS: We collected information regarding all thyroid/parathyroid surgeries performed by endocrine surgeons at our institution before and after the implementation of the multi-intervention enhanced recovery after surgery pathway. We compared relevant outcomes for all cases 1 year before (n = 479) and 1 year after (n = 166) implementation of the pathway. We also compared outcomes between enhanced recovery after surgery patient groups with varying levels of enhanced recovery after surgery compliance. RESULTS: Enhanced recovery after surgery was associated with a significant decrease in total length of stay (9.2 vs 7.5 hours, P < .0001). Whereas there was no significant decrease in all-cause unanticipated postoperative admissions, there was a decrease in patient-initiated admissions in the Enhanced recovery after surgery group. There was also a significant decrease in mean postoperative morphine milligram equivalents (14.4 vs 16.2 vs 24.8, P = .0015), average daily morphine milligram equivalents (25.6 vs 45.6 vs 53, P < .0001), and average daily pain scores (1.89 vs 2.38 vs 2.74, P = .0045) in the Enhanced recovery after surgery group (particularly with increasing Enhanced recovery after surgery compliance). There were no significant differences in the requirement for postoperative antiemetics or in the post-anesthesia care unit length of stay. CONCLUSION: This study demonstrates a significant benefit from Enhanced recovery after surgery pathways for thyroidectomies and parathyroidectomies, even with initial data and a staggered roll-out plan. Further directions include a follow-up study once we reach a higher level of institutional compliance with all components of the Enhanced Recovery After Surgery pathway and a prospective trial to identify the relative significance of different portions of the Enhanced Recovery after Surgery pathway, particularly the superficial cervical plexus block.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Machado N, Mortlock R, Maduka R, et al. Early observations with an ERAS pathway for thyroid and parathyroid surgery: Moving the goalposts forward. Surgery. 2023. PMID: 37973430. doi:10.1016/j.surg.2023.06.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。